Premium
The American Society of Peritoneal Surface Malignancies Multi‐Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score
Author(s) -
Sleightholm Richard,
Foster Jason M.,
Smith Lynette,
Ceelen Wim,
Deraco Marcello,
Yildirim Yusuf,
Levine Edward,
MuñozCasares Cristobal,
Glehen Olivier,
Patel Asish,
Esquivel Jesus
Publication year - 2016
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.24406
Subject(s) - medicine , hyperthermic intraperitoneal chemotherapy , cytoreductive surgery , taxane , ovarian cancer , chemotherapy , oncology , stage (stratigraphy) , population , surgery , cancer , breast cancer , paleontology , environmental health , biology
Background Standard treatment for ovarian epithelial cancer (OEC) consists of cytoreductive surgery (CRS) and a platinum–taxane chemotherapy combination. There is increasing interest in evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage IIIC/IV disease. The peritoneal surface disease severity score (PSDSS) was introduced as a basis to improve patient selection for this therapy in OEC. Methods The charts of 1,051 patients with advanced OEC who underwent CRS/HIPEC were retrospectively evaluated using the following preoperatively obtained criteria: symptoms, peritoneal dissemination, and tumor histology. Overall survival was analyzed according to PSDSS as well as the timings and agents used during CRS/HIPEC. Results Median survival for all 1,051 patients was 73.4 months. PSDSS information was available for 553 patients. Survival correlated negatively with PSDSS ( P < 0.001). Furthermore, combining PSDSS scores into I/II and III/IV described two distinct patient populations with vastly different outcomes, 100 versus 55 months, respectively ( P < 0.001). Multivariate analysis failed to describe any differences between timings of HIPEC or chemotherapy agents used. Conclusion PSDSS was capable of identifying a better surviving patient population in advanced‐stage OEC. While randomized trials to evaluate the benefit of HIPEC are needed, the PSDSS may be a useful tool for selecting and stratifying OEC patients in clinical trials. J. Surg. Oncol. 2016;114:779–784 . © 2016 2016 Wiley Periodicals, Inc.